Haya Taitel - 13 Sep 2023 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role
Director
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Issuer symbol
ENTX
Transactions as of
13 Sep 2023
Net transactions value
$0
Form type
4
Filing time
14 Sep 2023, 17:03:38 UTC
Previous filing
24 Aug 2023
Next filing
03 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTX Stock Option (right to buy) Award $0 +33,368 $0.000000 33,368 13 Sep 2023 Ordinary Shares, par value NIS 0.0000769 per share 33,368 $0.8090 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on June 6, 2023, subject to approval by the Company's shareholders, which was obtained on September 13, 2023. The options vest ratably on an annual basis over a three-year period that commenced on June 6, 2023.